STAAR SURGICAL sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive
The independent financial analyst theScreener just awarded an improved star rating to STAAR SURGICAL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date October 29, 2021, the closing price was USD 118.46 and its target price was estimated at USD 90.87.STAAR Surgical designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company is a manufacturer of lenses used worldwide in corrective or refractive surgery. The company's principal products are implantable Collamer lenses (ICLs) used in refractive surgery and intraocular lenses (IOLs) used in cataract surgery. ICLs, consisting of the company's ICL family of products, including the Toric implantable Collamer lenses and EVO+ Visian ICL, are intraocular lenses used to correct refractive conditions. IOLs are prosthetic intraocular lenses used to restore vision that has been affected by cataracts.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.